Compare Marsh & McLennan Companies, Inc. (MRSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Neurocrine Biosciences Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.13 (market cap $84.31B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.9× Neurocrine Biosciences Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MRSH | NBIX | |
|---|---|---|
Market Cap | $84.31B | $14.36B |
Volume | 3,948,947 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $207.02 | $185.50 |
52-Week Low | $157.32 | $123.10 |
Typical Hold Time | 109 Days | 23 Days |
Enterprise Value | $104.99B | $14.37B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals, with revenue growing to $26.98B in 2025 and net income of $4.16B, supported by consistent earnings beats. Recent news highlights the completion of the Accel Holdings acquisition, potentially enhancing its advisory services footprint. Valuation ratios include a P/E of 21.57 and ROE of 25.72%, indicating solid profitability.
The outlook for MRSH is positive, driven by earnings momentum and strategic acquisitions, but risks include high debt levels and competitive pressures. Analysts maintain a consensus price target of $202.71, suggesting upside potential, though the majority recommend Hold. Investors should weigh growth opportunities against execution risks and market volatility.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
